Table 1.

Clinicopathologic characteristics on surgically resected primary lung ADC

	Test cohort (n = 40)	Validation cohort (n = 63)	P
Age, y			0.20
Mean (range)	59 (47–67)	59 (32–72)
Gender number (%)
Male	23 (58)	28 (44)	0.23
Female	17 (42)	35 (56)
Smoking (pack year) number (%)
Never smoker	16 (40)	33 (52)	0.09
<20	3 (8)	10 (16)
≥20	21 (52)	20 (32)
TP53 genotype number (%)			0.49
Arg/Arg	20 (50)	24 (38)
Arg/Pro	16 (40)	33 (52)
Pro/Pro	4 (10)	6 (10)
Driver oncogene mutation number (%)
Negative	14 (35)	28 (44)	0.34
Positive	26 (65)	35 (56)
EGFR mutation	19	28
KRAS mutation	3	7
HER2 mutation	3	0
BRAF mutation	1	0
Driver oncogene fusion number (%)
Negative	36 (90)	NE
Positive	4 (10)	NE
ALK fusion	2	NE
RET fusion	0	NE
ROS1 fusion	2	NE
TNM stage at initial diagnosis number (%)			0.83
IA	6 (15)	5 (8)
IB	5 (13)	12 (19)
IIA	4 (10)	10 (16)
IIB	2 (5)	2 (3)
IIIA	18 (45)	26 (41)
IIIB	2 (5)	0
IV	3 (8)	8 (13)
TNM stage at recurrence number (%)			0.32
IA	0	0
IB	0	0
IIA	0	0
IIB	0	0
IIIA	0	0
IIIB	0	0
IV	0	0
Recurrent portion			1
Local/regional	2 (5)	3 (5)
Metastasis	38 (95)	60 (95)
M1a	22	28
M1b	16	32
Platinum-based regimens number (%)			0.44
Platinum + paclitaxel	30 (75)	42 (67)
Platinum + gemcitabine	9 (23)	14 (22)
Platinum + docetaxel	0	4 (6)
Platinum + pemetrexed	0	2 (3)
Platinum + vinorelbine	1 (2)	1 (2)
Tumor response number (%)
Responder	16 (40)	18 (29)	0.31
CR	1	0
PR	15	18
Nonresponder	24 (60)	45 (71)
SD	21	35
PD	3	10

NOTE: The P value from the Fisher's exact test.

Abbreviations: NE, not examined; Platinum, cisplatin or carboplatin.